JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v9i4.10402ArticleAlleviative Treatments for Alzheimer’s Disease and Early Ecological Intervention Strategies in the Communityhttps://artdesignp.com/journal/JCNR/9/4/10.26689/jcnr.v9i4.10402ZhuangPeihua,WangDongxing,ZhaoShuyu,LuPeifang2025942025-04-29According to the data from the 7th national population census, the population aged 65 and above in China has reached 13.50%, indicating that the country has entered a deeply aging society. The health issues of the elderly have become a significant concern for society. Common brain diseases among the elderly, including cerebrovascular diseases, genetic factors, or long-term solitary living, can all lead to dementia, with Alzheimer’s disease (AD) being the most common. Early symptoms of AD mainly include memory loss and difficulty concentrating, which are often mistaken for normal aging or stress-related issues and thus overlooked. AD lacks specific biomarkers and effective auxiliary diagnostic methods, making it difficult to accurately diagnose with existing imaging and neuroprotein indicators. Therefore, early detection of AD is very challenging. This article explores community-based early detection and intervention strategies from the perspectives of existing mechanism research, clinical manifestations, modern drug treatments, innovative explorations in traditional medicine, and community-appropriate technologies, aiming to construct an ecological management strategy.

GBD 2019 Dementia Forecasting Collaborators, 2022, Estimation of the Global Prevalence of Dementia in 2019 and Forecasted Prevalence in 2050: An Analysis for the Global Burden of Disease Study 2019. Lancet Public Health, 7: e105–25.

Al-Ghraiybah NF, Wang J, Alkhalifa AE, et al., 2022, Glial Cell-Mediated Neuroinflammation in Alzheimer’s Disease. Int J Mol Sci, 23: 10572.

Monteiro AR, Barbosa DJ, Remiao F, et al., 2023, Alzheimer’s Disease: Insights and New Prospects in Disease Pathophysiology, Biomarkers and Disease-Modifying Drugs. Biochem Pharmacol, 211: 115522.

Nasreddine Z, Garibotto V, Kyaga S, et al., 2023, The Early Diagnosis of Alzheimer’s Disease: A Patient-Centred Conversation with the Care Team. Neurol Ther, 12: 11–23.

Da Mesquita S, Ferreira AC, Sousa JC, et al., 2016, Insights on the Pathophysiology of Alzheimer’s Disease: The Crosstalk Between Amyloid Pathology, Neuroinflammation and the Peripheral Immune System. Neurosci Biobehav Rev, 68: 547–562.

Serrano-Pozo A, Das S, Hyman BT, 2021, APOE and Alzheimer’s Disease: Advances in Genetics, Pathophysiology, and Therapeutic Approaches. Lancet Neurol, 20: 68–80.

Chouliaras L, Rutten BP, Kenis G, et al., 2010, Epigenetic Regulation in the Pathophysiology of Alzheimer’s Disease. Prog Neurobiol, 90: 498–510.

Livingston G, Huntley J, Sommerlad A, et al., 2020, Dementia Prevention, Intervention, and Care: 2020 Report of the Lancet Commission. Lancet, 396: 413–446.

Serrano-Pozo A, Das S, Hyman BT, 2021, APOE and Alzheimer’s Disease: Advances in Genetics, Pathophysiology, and Therapeutic Approaches. Lancet Neurol, 20: 68–80.

2021 Alzheimer’s Disease Facts and Figures, 2021, Alzheimers Dement, 17(3): 327–406.

Cerejeira J, Lagarto L, Mukaetova-Ladinska EB, 2012, Behavioral and Psychological Symptoms of Dementia. Front Neurol, 3: 73.

Jones D, Pelak V, Rogalski E, 2024, Atypical Presentations of Alzheimer Disease. Continuum (Minneap Minn), 30(6): 1614–1641.

Singh R, Sadiq NM, 2024, Cholinesterase Inhibitors. StatPearls, Treasure Island, FL: StatPearls Publishing, Florida.

Adlimoghaddam A, Neuendorff M, Roy B, et al., 2018, A Review of Clinical Treatment Considerations of Donepezil in Severe Alzheimer’s Disease. CNS Neurosci Ther, 24: 876–888.

Cui X, Guo YE, Fang JH, et al., 2019, Donepezil, a Drug for Alzheimer’s Disease, Promotes Oligodendrocyte Generation and Remyelination. Acta Pharmacol Sin, 40: 1386–1393.

Solntseva EI, Kapai NA, Popova OV, et al., 2014, The Involvement of Sigma1 Receptors in Donepezil-Induced Rescue of Hippocampal LTP Impaired by Beta-Amyloid Peptide. Brain Res Bull, 106: 56–61.

Zhang X, Lian S, Zhang Y, et al., 2022, Efficacy and Safety of Donepezil for Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. Clin Neurol Neurosurg, 213: 107134.

Jann MW, 2000, Rivastigmine, a New-Generation Cholinesterase Inhibitor for the Treatment of Alzheimer’s Disease. Pharmacotherapy, 20: 1–12.

Jann MW, Shirley KL, Small GW, 2002, Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors. Clin Pharmacokinet, 41: 719–739.

Rosler M, Anand R, Cicin-Sain A, et al., 1999, Efficacy and Safety of Rivastigmine in Patients with Alzheimer’s Disease: International Randomised Controlled Trial. BMJ, 318: 633–638.

Khoury R, Rajamanickam J, Grossberg GT, 2018, An Update on the Safety of Current Therapies for Alzheimer’s Disease: Focus on Rivastigmine. Ther Adv Drug Saf, 9: 171–178.

Farlow M, Anand R, Messina J Jr, et al., 2000, 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease. Eur Neurol, 44: 236–241.

Inglis F, 2002, The Tolerability and Safety of Cholinesterase Inhibitors in the Treatment of Dementia. Int J Clin Pract Suppl, 127: 45–63.

Karaman Y, Erdogan F, Koseoglu E, et al., 2005, 12-Month Study of the Efficacy of Rivastigmine in Patients with Advanced Moderate Alzheimer’s Disease. Dement Geriatr Cogn Disord, 19: 51–56.

Hansen RA, Gartlehner G, Webb AP, et al., 2008, Efficacy and Safety of Donepezil, Galantamine, and Rivastigmine for the Treatment of Alzheimer’s Disease: A Systematic Review and Meta-Analysis. Clin Interv Aging, 3: 211–225.

Scott LJ, Goa KL, 2000, Galantamine: A Review of its Use in Alzheimer’s Disease. Drugs, 60: 1095–1122.

Lilienfeld S, 2002, Galantamine – A Novel Cholinergic Drug with a Unique Dual Mode of Action for the Treatment of Patients with Alzheimer’s Disease. CNS Drug Rev, 8: 159–176.

Raskind MA, 2003, Update on Alzheimer Drugs (Galantamine). Neurologist, 9: 235–240.

Razay G, Wilcock GK, 2008, Galantamine in Alzheimer’s Disease. Expert Rev Neurother, 8: 9–17. doi:10.1586/14737175.8.1.9.

Richarz U, Gaudig M, Rettig K, et al., 2014, Galantamine Treatment in Outpatients with Mild Alzheimer’s Disease. Acta Neurol Scand, 129: 382–392.

Olin J, Schneider L, 2002, Galantamine for Alzheimer’s Disease. Cochrane Database Syst Rev, 3: CD001747.

Fisher AA, Davis MW, 2008, Prolonged QT Interval, Syncope, and Delirium with Galantamine. Ann Pharmacother, 42: 278–283.

Johnson JW, Kotermanski SE, 2006, Mechanism of Action of Memantine. Curr Opin Pharmacol, 6: 61–67.

Reisberg B, Doody R, Stoffler A, et al., 2003, Memantine in Moderate-to-Severe Alzheimer’s Disease. N Engl J Med, 348:1333–1341.

Farlow MR, Graham SM, Alva G, 2008, Memantine for the Treatment of Alzheimer’s Disease: Tolerability and Safety Data from Clinical Trials. Drug Saf, 31: 577–585.

Vitek GE, Decourt B, Sabbagh MN, 2023, Lecanemab (BAN2401): An Anti-Beta-Amyloid Monoclonal Antibody for the Treatment of Alzheimer Disease. Expert Opin Investig Drugs, 32(2):89–94.

Tampi RR, Forester BP, Agronin M, 2021, Aducanumab: Evidence from Clinical Trial Data and Controversies. Drugs Context, 10: 1–9.

Cummings J, Aisen P, Apostolova L, et al., 2021, Aducanumab: Appropriate Use Recommendations. J Prev Alzheimers Dis, 8: 398–410.

Budd Haeberlein S, Aisen P, et al., 2022, Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease. J Prev Alzheimers Dis, 9: 197–210.

Esai Inc, Biogen, 2023, Lequembi: Prescribing Information. Nutley, NJ: Esai Inc, United Kingdom.

van Dyck CH, Swanson CJ, Aisen P, et al., 2023, Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine, 388: 9–21.

Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, et al., 2020, Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer’s Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. American Journal of Geriatric Psychiatry, 28: 383–400.

Stahl SM, 2016, Mechanism of Action of Brexpiprazole: Comparison With Aripiprazole. CNS Spectrums, 21: 1–6.

Yunusa I, Rashid N, Demos GN, et al., 2022, Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-Analysis. Advances in Therapy, 39: 1993–2008.

Merck, 2023, Merck Receives Approval for BELSOMRA (Suvorexant) C-IV Label Update to Include Findings From Study of Insomnia in Patients With Mild-to-Moderate Alzheimer’s Disease. Internal Report.

Stahl SM, 2016, Mechanism of Action of Suvorexant. CNS Spectrums, 21: 215–218.

Hanazawa T, Kamijo Y, 2019, Effect of Suvorexant on Nocturnal Delirium in Elderly Patients With Alzheimer’s Disease: A Case-Series Study. Clinical Psychopharmacology and Neuroscience, 17: 547–550.

Herring WJ, Ceesay P, Snyder E, et al., 2020, Polysomnographic Assessment of Suvorexant in Patients With Probable Alzheimer’s Disease Dementia and Insomnia: A Randomized Trial. Alzheimer’s and Dementia, 16: 541–551.

Rhyne DN, Anderson SL, 2015, Suvorexant in Insomnia: Efficacy, Safety and Place in Therapy. Therapeutic Advances in Drug Safety, 6: 189–195.

Gates EJ, Bernath AK, Klegeris A, 2022, Modifying the Diet and Gut Microbiota to Prevent and Manage Neurodegenerative Diseases. Reviews in Neuroscience, 33(7): 767–787.

Ettcheto M, Busquets O, Cano A, Sanchez-Lopez E, Manzine PR, Espinosa-Jimenez T, et al., 2021, Pharmacological Strategies to Improve Dendritic Spines in Alzheimer’s Disease. Journal of Alzheimer’s Disease, 82(S1): S91–S107.

Peng G, Li M, Meng Z, 2023, Polysaccharides: Potential Bioactive Macromolecules for Alzheimer’s Disease. Frontiers in Nutrition, 10: 1249018.

Martins M, Silva R, Pinto MM, et al., 2020, Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer’s Disease. Pharmaceuticals, 13(9): 242.

Klose J, Griehl C, RoBner S, et al., 2022, Natural Products From Plants and Algae for Treatment of Alzheimer’s Disease: A Review. Biomolecules, 12(5): 694.

Ma Y, Liu S, Zhou Q, et al., 2024, Approved Drugs and Natural Products at Clinical Stages for Treating Alzheimer’s Disease. Chinese Journal of Natural Medicine, 22(8): 699–710.

Wang X, Sun G, Feng T, et al., 2019, Sodium Oligomannate Therapeutically Remodels Gut Microbiota and Suppresses Gut Bacterial Amino Acids–Shaped Neuroinflammation to Inhibit Alzheimer’s Disease Progression. Cell Research, 29(10): 787–803.

Xiao S, Chan P, Wang T, et al., 2021, A 36-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial of Sodium Oligomannate for Mild-to-Moderate Alzheimer’s Dementia. Alzheimer’s Research and Therapy, 13(1): 62.

Wang Y, Li H, et al., 2021, Efficacy and Safety of GV-971 in Patients With Mild-to-Moderate Alzheimer’s Disease: A Phase 3 Randomized Clinical Trial. Alzheimer’s and Dementia, 17(Suppl 10): e058107.

Yang H, 2014, Research Progress on the Treatment of Alzheimer’s Disease With Chinese Herbal Extracts. Journal of Hubei University of Chinese Medicine, 16(1): 113–115.

Li Y, Liu Y, Zhang G, et al., 2024, Research Progress on the Treatment of Alzheimer’s Disease With Single Chinese Herbal Medicines. Journal of Changzhi Medical College, 38(6): 470–474.

Xue Y, Li Y, Wang Y, et al., 2024, Synergistic Effect and Mechanism of Ginkgo Biloba Extract Combined With Donepezil on Alzheimer’s Disease Model Rats. China Pharmaceuticals, 33(10): 59–65.

Zhang N, Nao J, Dong X, 2023, Neuroprotective Mechanisms of Salidroside in Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Preclinical Studies. Journal of Agricultural and Food Chemistry, 71(46): 17597–17614.

Li Y, Wang H, Yang L, et al., 2024, Research Progress on the Protective Effect and Mechanism of Ganoderma Lucidum Polysaccharides in Neuroinflammatory Degenerative Diseases. Journal of Shanxi University of Chinese Medicine, 25(9): 1038–1042, 1062.

Lin C, Huang Z, Wen S, et al., 2024, Study on the Effects of Tenuifolin From Polygala Tenuifolia on Liver and Kidney Based on a Mouse Model of Alzheimer’s Disease. Asia-Pacific Traditional Medicine, 20(12): 22–25.

Li Q, Zhang Y, Li R, et al., 2022, Study on the Mechanism of Ophiopogonin D in Improving Cognitive Function of Alzheimer’s Disease Model Rats. Journal of Regional Anatomy and Operative Surgery, 31(12): 1046–1051.

Li L, Zhang L, 2012, Characteristics of the Effects of Traditional Chinese Medicine in the Treatment of Alzheimer’s Disease. Progress in Biochemistry and Biophysics, 39(8): 816–828.

Zhang L, Wang Y, Zhou J, et al., 2018, Observation on Curative Effect of Dihuang Yinzi in the Treatment of Alzheimer’s Disease and Discussion on Its Mechanism. China Journal of Chinese Materia Medica, 33(11): 4948–4952.

Liang C, Wang H, Shen S, et al., 2025, Study on the Pharmacodynamics and Mechanism of Gegen-Zhimu Herb Pair in the Prevention and Treatment of Alzheimer’s Disease Based on UHPLC-Q/TOF-MS Metabolomics Strategy. Pharmaceutical Practice and Service, 43(1): 30–40.

Wang Y, Wu M, Song W, et al., 2024, Research Progress on the Pathogenesis of Alzheimer’s Disease and the Treatment of Traditional Chinese Medicine Based on Gut Microbiota. Shaanxi Journal of Traditional Chinese Medicine, 45(12): 1718–1721.

Iyaswamy A, Krishnamoorthi SK, Liu YW, et al., 2020, Yuan-Hu Zhi Tong Prescription Mitigates Tau Pathology and Alleviates Memory Deficiency in the Preclinical Models of Alzheimer’s Disease. Frontiers in Pharmacology, 11: 584770.

Wang X, 2021, Network Meta-Analysis of the Effects of Acupuncture-Related Therapies on Cognitive Function in Patients With Mild to Moderate Alzheimer’s Disease, thesis, Hubei University of Chinese Medicine.

Luo Y, Shan X, Song J, et al., 2024, Exploring the Mechanism of Acupuncture and Moxibustion in Preventing and Treating Alzheimer’s Disease Based on Neuronal Cell Cycle Re-Entry. Acupuncture Research, 49(11): 1205–1212.

Tang Y, Zhang M, 2024, Clinical Research Progress of Acupuncture Treatment for Alzheimer’s Disease. Traditional Chinese Medicine, 13(11): 3103–3107.

Lu S, Shao X, Tang Y, et al., 2008, Neural Cell Adhesion Mechanism of Electroacupuncture Promoting Synaptic Plasticity of Hippocampal Neurons in Alzheimer’s Disease Model Mice (SAMP8). Chinese Journal of Rehabilitation Medicine, 23(12): 1057–1060.

Wang Y, Kong L, Li W, et al., 2017, Effects of Electroacupuncture at Different Frequencies on Learning-Memory Ability and Partial Mechanism in Rats With Alzheimer’s Disease. Chinese Acupuncture and Moxibustion, 37(6): 629–636.

Tang S, Du Y, Xiao J, et al., 2018, Effects of Acupuncture and Moxibustion on Up-Regulating Serum AB Internalization Enzymes, Learning and Memory Abilities, and B-Amyloid Protein Deposition in Rats With Alzheimer’s Disease. Acupuncture Research, 43(11): 692–697.

Ke C, Shan S, Tan Y, et al., 2024, Signaling Pathways in the Treatment of Alzheimer’s Disease With Acupuncture: A Narrative Review. Acupuncture Medicine, 42(4): 216–230.

Du K, Yang S, Wang J, Zhu G, 2022, Acupuncture Interventions for Alzheimer’s Disease and Vascular Cognitive Disorders: A Review of Mechanisms. Oxidative Medicine and Cellular Longevity, 2022: 6080282.

Yang W, Dong W, 2020, Mechanisms of Electroacupuncture for Improving Alzheimer’s Disease From Reducing B Amyloid Protein Level. Acupuncture Research, 45(5): 426–431.

Huang TI, Hsieh CL, 2021, Effects of Acupuncture on Oxidative Stress Amelioration via Nrf2/ARE-Related Pathways in Alzheimer and Parkinson Diseases. Evidence-Based Complementary and Alternative Medicine, 2021: 6624976.

Jiang YH, He JK, Li R, et al., 2022, Mechanisms of Acupuncture in Improving Alzheimer’s Disease Caused by Mitochondrial Damage. Chinese Journal of Integrative Medicine, 28(3): 272–280.

Zhang L, Han W, Zhu C, et al., 2019, Study on the Regulation of PI3K/Akt/mTOR Signaling Pathway by Moxibustion at Du Meridian to Enhance Autophagy Level in APP/PS1 Double Transgenic AD Mice. Chinese Acupuncture and Moxibustion, 39(12): 1313–1319.

Zhou Y, Jia J, 2008, Clinical Observation of Acupoint Catgut Embedding Therapy for Alzheimer’s Disease. Chinese Acupuncture and Moxibustion, 28(1): 37–40.

Sun X, Song L, Zhuang P, et al., 2019, Intervention Study of Traditional Auricular Therapy Combined With Modern Finger Exercises on Patients With Mild Cognitive Impairment. Chinese Primary Health Care, 33(2): 72–73,82.

Li Y, Wang X, Shan S, et al., 2021, Clinical Application of Music Therapy in the Treatment of Alzheimer’s Disease. China Modern Medicine, 28(16): 252–254.

Wang X, Guo Q, Cai M, et al., 2021, The Influence and Mechanism of Music Therapy on Cognitive Function of Senile Dementia. Chinese Journal of Convalescent Medicine, 30(5): 483–485.

Jiang Y, 2024, A Review of the Current Research Status of Music Therapy Intervention in Recent Memory Impairment of Elderly People With Early Dementia. Contemporary Music, 2024(3): 189–192.

Zhang Y, Wang S, Huang R, et al., 2024, Meta-Analysis of the Intervention Effect of Music Therapy on Patients With Alzheimer’s Disease. Chinese General Practice, 27(12): 1511–1518.

Yang X, Chen W, Sun J, et al., 2024, Theoretical Discussion on the Prevention and Treatment of Vascular Dementia With Traditional Chinese Medicine Guidance. Chinese and Foreign Medical Research on Cardiovascular and Cerebrovascular Diseases, 22(22): 4207–4209.

Zhang Y, Huang S, Wu R, et al., 2024, Effects of Eight-Section Brocade Combined With Cognitive Training on Elderly Patients With Multiple Chronic Conditions and Cognitive Frailty. Chinese and Foreign Medical Research, 3(31): 135–137.

Yu X, 2021, The Effect of Guided Prescription Combined With Cognitive Training on Cognitive Function and Activities of Daily Living in Patients With Vascular Dementia. Reflexotherapy and Rehabilitation Medicine, 2(8): 7–9.